755 related articles for article (PubMed ID: 26984188)
1. Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging.
Hamelin L; Lagarde J; Dorothée G; Leroy C; Labit M; Comley RA; de Souza LC; Corne H; Dauphinot L; Bertoux M; Dubois B; Gervais P; Colliot O; Potier MC; Bottlaender M; Sarazin M;
Brain; 2016 Apr; 139(Pt 4):1252-64. PubMed ID: 26984188
[TBL] [Abstract][Full Text] [Related]
2. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease.
Hamelin L; Lagarde J; Dorothée G; Potier MC; Corlier F; Kuhnast B; Caillé F; Dubois B; Fillon L; Chupin M; Bottlaender M; Sarazin M
Brain; 2018 Jun; 141(6):1855-1870. PubMed ID: 29608645
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease.
Fan Z; Okello AA; Brooks DJ; Edison P
Brain; 2015 Dec; 138(Pt 12):3685-98. PubMed ID: 26510952
[TBL] [Abstract][Full Text] [Related]
4. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
[TBL] [Abstract][Full Text] [Related]
5. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.
Rabinovici GD; Furst AJ; Alkalay A; Racine CA; O'Neil JP; Janabi M; Baker SL; Agarwal N; Bonasera SJ; Mormino EC; Weiner MW; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ
Brain; 2010 Feb; 133(Pt 2):512-28. PubMed ID: 20080878
[TBL] [Abstract][Full Text] [Related]
6. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease.
Kreisl WC; Lyoo CH; McGwier M; Snow J; Jenko KJ; Kimura N; Corona W; Morse CL; Zoghbi SS; Pike VW; McMahon FJ; Turner RS; Innis RB;
Brain; 2013 Jul; 136(Pt 7):2228-38. PubMed ID: 23775979
[TBL] [Abstract][Full Text] [Related]
7. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
[TBL] [Abstract][Full Text] [Related]
9. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
[TBL] [Abstract][Full Text] [Related]
10. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer's disease patients and control subjects.
Varrone A; Oikonen V; Forsberg A; Joutsa J; Takano A; Solin O; Haaparanta-Solin M; Nag S; Nakao R; Al-Tawil N; Wells LA; Rabiner EA; Valencia R; Schultze-Mosgau M; Thiele A; Vollmer S; Dyrks T; Lehmann L; Heinrich T; Hoffmann A; Nordberg A; Halldin C; Rinne JO
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):438-46. PubMed ID: 25412766
[TBL] [Abstract][Full Text] [Related]
13. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
[TBL] [Abstract][Full Text] [Related]
14. Quantification of [18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimer's disease patients.
Golla SS; Boellaard R; Oikonen V; Hoffmann A; van Berckel BN; Windhorst AD; Virta J; Haaparanta-Solin M; Luoto P; Savisto N; Solin O; Valencia R; Thiele A; Eriksson J; Schuit RC; Lammertsma AA; Rinne JO
J Cereb Blood Flow Metab; 2015 May; 35(5):766-72. PubMed ID: 25649991
[TBL] [Abstract][Full Text] [Related]
15. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.
Villeneuve S; Rabinovici GD; Cohn-Sheehy BI; Madison C; Ayakta N; Ghosh PM; La Joie R; Arthur-Bentil SK; Vogel JW; Marks SM; Lehmann M; Rosen HJ; Reed B; Olichney J; Boxer AL; Miller BL; Borys E; Jin LW; Huang EJ; Grinberg LT; DeCarli C; Seeley WW; Jagust W
Brain; 2015 Jul; 138(Pt 7):2020-33. PubMed ID: 25953778
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.
Murray ME; Lowe VJ; Graff-Radford NR; Liesinger AM; Cannon A; Przybelski SA; Rawal B; Parisi JE; Petersen RC; Kantarci K; Ross OA; Duara R; Knopman DS; Jack CR; Dickson DW
Brain; 2015 May; 138(Pt 5):1370-81. PubMed ID: 25805643
[TBL] [Abstract][Full Text] [Related]
17. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
[TBL] [Abstract][Full Text] [Related]
18. Microglial response to increasing amyloid load saturates with aging: a longitudinal dual tracer in vivo μPET-study.
Blume T; Focke C; Peters F; Deussing M; Albert NL; Lindner S; Gildehaus FJ; von Ungern-Sternberg B; Ozmen L; Baumann K; Bartenstein P; Rominger A; Herms J; Brendel M
J Neuroinflammation; 2018 Nov; 15(1):307. PubMed ID: 30400912
[TBL] [Abstract][Full Text] [Related]
19. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
20. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.
Ni R; Gillberg PG; Bergfors A; Marutle A; Nordberg A
Brain; 2013 Jul; 136(Pt 7):2217-27. PubMed ID: 23757761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
